With the CDC reporting over 23,000 hospitalizations for influenza, The American Society of Health-System Pharmacists are reporting a shortage of oseltamivir, otherwise known as Tamiflu, in
several doses by five generic manufacturers. "A reason for the shortages was not listed by the ASHP, but there are still doses available from other producers including Genentech, Ajanta, Alvogen and
Strides Pharma," per Endpoints. "A hard date for when the supply will return to normal was not settled, but the ASHP report stated that Teva should be back up to capacity by the end of
December."
Read the whole story at Endpoints News »